Close
Nordic 9Nordic 9

Avego Bioscience Capital (investor - Private Equity)

United States avego.com
See something wrong or missing? Let us know
Offices:New York

Avego Bioscience Capital is an American private equity company doing mid to late stage private biotech investments

Average round investment:110M USD
Average number per year:1.5
Distribution: 2025 (2)2024 (1)
Portfolio companies: Netherlands myTomorrowsUnited Kingdom CellCentricSwitzerland Alentis Therapeutics
Mostly invests in: Netherlands Netherlands (1) Health services (3)

3 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Avego Bioscience Capital

Name Criteria
United Kingdom AstraZeneca
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Health services, Biotech, Manufacturing, Software Services
  • Similar business models: B2B
  • Common investees countries: Netherlands, United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Switzerland Endeavour Vision
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Saudi Arabia's Public Investment Fund
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Health services, Manufacturing, Marketplace
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
United States Redmile Group
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Software Services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
United Kingdom Mayfair Equity Partners
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Manufacturing, Marketplace, Software Services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
United States Access Biotechnology
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
United States Frazier Life Sciences
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
South Korea Hyundai Motor Company
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Manufacturing, Software Services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.6
  • Active last 12 months: Yes
Denmark Kirkbi A/S
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Health services, Manufacturing, Software Services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.4
  • Active last 12 months: Yes
Investcorp
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Manufacturing, Marketplace, Software Services
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.6
  • Active last 12 months: Yes
Top